{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":17,"youtube":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05280470\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IDeate-Lung01","nct_id":"NCT05280470","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ideate-lung01-nct05280470. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IDeate-Lung01","arms":[{"description":"Participants will be randomized to receive I-DXd at 8 mg/kg.","label":"Ifinatamab Deruxtecan (8 mg/kg)","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive I-DXd at 12 mg/kg.\n\nThis arm will consist of participants from Part 1 and Part 2 who receive I-DXd 12 mg/kg.","label":"Ifinatamab Deruxtecan (12 mg/kg)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2026-12-15","type":"ESTIMATED"},"conditions":["Extensive-stage Small-cell Lung Cancer"],"enrollment":{"count":187,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ifinatamab Deruxtecan (I-DXd)","type":"DRUG"}],"last_update":"2026-02-25","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-03-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC","timeFrame":"Up to approximately 36 months"}],"references":[{"citation":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, Hu H, Qian M, Singh J, Godard J, Tang M, Ahn MJ. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. 2026 Feb;44(4):261-273. doi: 10.1200/JCO-25-02142. Epub 2025 Oct 14.","pmid":"41086386","type":"DERIVED"}],"start_date":{"date":"2022-03-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","url":"https://clinicaltrials.gov/study/NCT05280470"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ideate-lung01-nct05280470"}